DUBLIN – Scottish startup Adorx Therapeutics Ltd. is the latest contender to tackle the knotty problem of immunosuppression in the tumor microenvironment through adenosine receptor inhibition. The Edinburgh-based firm raised $10 million to take forward an adenosine receptor A2A antagonist and a dual blocker of the A2A and A2B receptors.